 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Alexion Pharmaceuticals, Inc.
 |
Alexion Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Alexion Pharmaceuticals can't suppress its enthusiasm for treating immune functions gone awry. The firm develops drugs that inhibit certain immune system functions that cause autoimmune, cardiovascular, and neurological diseases. One lead candidate, developed with Proctor & Gamble, targets inflammation following cardiopulmonary bypass surgery, and another candidate targets rheumatoid arthritis and lupus. Alexion made a splash by curing spinal injuries in rodents with genetically altered pig cells: Its work in xenotransplantation is in concert with development of a T-cell inhibitor technology (used for xenotransplantation) to treat multiple sclerosis, Parkinson's disease, and other neurological disorders.
COMPETITION |
 |
AVANT Immunotherapeutics, Inc. (AVAN)
Abbott Laboratories (ABT)
BioCryst Pharmaceuticals, Inc. (BCRX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: July
2000 Sales (mil.): 21.40
1-Yr. Sales Growth: 13.8%
Employees: 113
Revenue per employee: $189,380.53
KEY PEOPLE |
 |
Leonard Bell
CEO
Barry P. Luke
CFO
CONTACT INFO |
 |
25 Science Park
New Haven, CT 06511
US
Phone: 203-776-1790
Fax: 203-772-3655
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |